Skip to main content

Advertisement

SpringerLink
Log in

Quality assurance in clinical trials—the role of pathology

  • Annual Review Issue
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

In the last two decades, our knowledge about cancer genetics and cancer biology increased exponentially. Deep sequencing now allows rapid and cost-effective analysis of entire cancer genomes. Dysregulation of cell growth, cell survival, tissue homeostasis, and immune surveillance have been recognized as hallmarks of cancer. In parallel, diagnostic surgical pathology has been harmonized and consensus diagnostic criteria for cancer classification have been developed by initiatives of the World Health Organization, the International Agency for Research on Cancer, and the Union for International Cancer Control. Pharmaceutical companies developed novel drugs targeting specific molecules in signaling pathways, which has allowed the development of the concept of precision medicine. Now, we are facing a large number of clinical trials which bring together these advances and will explore efficacy of novel treatment regimens. Assessment of the efficacy of a new drug is often coupled with the simultaneous assessment of the capacity of tissue-based biomarkers to predict response of individual patients (companion diagnostics/precision medicine). Patients with histologically similar tumors might respond differently to the same drug. This review summarizes the diverse roles played by surgical pathologists involved in clinical trials, with a special focus on quality assurance of diagnostic, laboratory, and reporting standards.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Rock W, Piessevaux H, De SJ, Janssens M, De HG, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van CE, Tejpar S (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515

    Article  Google Scholar 

  2. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499

    Article  CAS  PubMed  Google Scholar 

  3. Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S, Ilson DH, Tjulandin S, Gotovkin E, Zhang Y, Hoang T, Sidhu R, Catenacci DVT (2015) Phase 3, randomized, double-blind, multicenter, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction cancer: RILOMET-1 Study. J Clin Oncol 33 (suppl.): Abstr. No. 4000

  4. Shah MA, Bang YJ, Lordick F, Tabernero J, Chen M, Hack SP, Phan S, Shames DS, Cunningham D (2015) METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC) J Clin Oncol 33 (suppl.): Abstr. No. 4012

  5. Röcken C, Höfler H, Hummel M, Meyermann R, Zietz C, Schirmacher P (2014) Participation in and support of clinical studies and other scientific investigations—Statement of the German Society for Pathology. Pathol Res Pract 210:705–712

    Article  PubMed  Google Scholar 

  6. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC, Gould M (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8:381–385

    Article  PubMed  Google Scholar 

  7. Sobin LH, Gospodarowicz M, Wittekind C (2010) International union against cancer (UICC) TNM classification of malignant tumours, 7th edn. Wiley-Liss, New York

    Google Scholar 

  8. Collins FS, Varmus H (2015) A new initiative on precision medicine. New Engl J Med 372:793–795

    Article  CAS  PubMed  Google Scholar 

  9. Gregory DM, Parfrey PS (2010) The breast cancer hormone receptor retesting controversy in Newfoundland and Labrador, Canada: lessons for the health system. Healthc Manag Forum 23:114–118

    Article  Google Scholar 

  10. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van d V, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145

    Article  CAS  PubMed  Google Scholar 

  11. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013

    Article  PubMed  Google Scholar 

  12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067–9072

    Article  PubMed  Google Scholar 

  13. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Toward complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Am J Clin Pathol 119:18–22

    Article  PubMed  Google Scholar 

  14. Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Röcken C, Dietel M (2010) KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 12:35–42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenovic S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ (2014) Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol 8:830–839

    Article  PubMed  Google Scholar 

  16. Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken JH, Dequeker EM (2014) Higher quality of molecular testing, an unfulfilled priority: results from external quality assessment for KRAS mutation testing in colorectal cancer. J Mol Diagn 16:371–377

    Article  CAS  PubMed  Google Scholar 

  17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 366:883–892

    Article  CAS  PubMed  Google Scholar 

  18. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46:225–233

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Yates LR, Campbell PJ (2012) Evolution of the cancer genome. Nat Rev Genet 13:795–806

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Humphries A, Cereser B, Gay LJ, Miller DS, Das B, Gutteridge A, Elia G, Nye E, Jeffery R, Poulsom R, Novelli MR, Rodriguez-Justo M, McDonald SA, Wright NA, Graham TA (2013) Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc Natl Acad Sci U S A 110:E2490–E2499

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Swanton C (2012) Intratumor heterogeneity: evolution through space and time. Cancer Res 72:4875–4882

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  CAS  PubMed  Google Scholar 

  23. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209

    Article  Google Scholar 

  24. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307

    Article  PubMed Central  PubMed  Google Scholar 

  25. Metzger ML, Behrens HM, Böger C, Haag J, Krüger S, Röcken C (2015) MET in gastric cancer—discarding a 10 % cutoff rule. Histopathology. doi:10.1111/his.12745

    PubMed  Google Scholar 

  26. Mathiak M, Warneke VS, Behrens HM, Haag J, Böger C, Krüger S, Röcken C (2015) Clinico-pathological characteristics of microsatellite instable gastric carcinomas revisited. Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000264

    PubMed  Google Scholar 

  27. Lordick F, Röcken C (2013) The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Ann Oncol 24:1135–1138

    Article  CAS  PubMed  Google Scholar 

  28. Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MP, Röcken C (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24:725–733

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, Raymond WA, Robbins PD, Farshid G (2012) Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Res Treat 134:617–624

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Choritz H, Busche G, Kreipe H (2011) Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch 459:283–289

    Article  PubMed Central  PubMed  Google Scholar 

  31. De RW, Claes B, Bernasconi D, De SJ, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De DS, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di FF, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van CE, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762

    Article  Google Scholar 

  32. Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  CAS  PubMed  Google Scholar 

  33. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Hofler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307

    Article  PubMed Central  PubMed  Google Scholar 

  34. Germany’s National Accreditation Body (2013) Guideline of the Pathology/Neuropathology sector committee for the validation of examination methods in immunohistology. http://dakks.de/en/content/guideline-pathologyneuropathology-sector-committee-validation-examination-methods

  35. Fitzgibbons PL, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, Haas TS, Karabakhtsian RG, Loykasek PA, Marolt MJ, Shen SS, Smith AT, Swanson PE, College of American Pathologists P, Laboratory Quality C (2014) Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 138:1432–1443

    Article  PubMed  Google Scholar 

  36. Roscoe DM, Hu YF, Philip R (2015) Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Rev Mol Diagn 15:869–880

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Christian-Albrechts-University, Arnold-Heller-Str. 3, Haus 14, 24105, Kiel, Germany

    Christoph Röcken

Authors
  1. Christoph Röcken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Röcken.

Ethics declarations

Conflict of interest

The author declares that he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Röcken, C. Quality assurance in clinical trials—the role of pathology. Virchows Arch 468, 83–92 (2016). https://doi.org/10.1007/s00428-015-1857-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-015-1857-x

Keywords

Search

Navigation